Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Articles

Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation

Jie Liu, Chengxiu Li, Wei Qu, Elaine Leslie, Challice L. Bonifant, Gregory S. Buzard, Joseph E. Saavedra, Larry K. Keefer and Michael P. Waalkes
Jie Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chengxiu Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Qu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elaine Leslie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Challice L. Bonifant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory S. Buzard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph E. Saavedra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry K. Keefer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael P. Waalkes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published June 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: June 2004 to January 2021

AbstractFull-text HTMLPDF
Total197835921460

Cited By

Article Information

Volume 3, Issue 6, pp. 709-714

PubMed 
15210857

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • April 2, 2004
  • December 16, 2003
  • March 18, 2004
  • Published first June 21, 2004.

Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Jie Liu1,
  2. Chengxiu Li1,
  3. Wei Qu1,
  4. Elaine Leslie1,
  5. Challice L. Bonifant2,
  6. Gregory S. Buzard3,
  7. Joseph E. Saavedra3,
  8. Larry K. Keefer2 and
  9. Michael P. Waalkes1
  1. 1Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at NIEHS, Research Triangle Park, North Carolina;
  2. 2Chemistry Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, Frederick, Maryland; and
  3. 3Basic Research Program, Science Applications International Corporation-Frederick, Frederick, Maryland
  1. Requests for reprints: Michael P. Waalkes, Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at NIEHS, mail drop F0-09, 111 Alexander Drive, Research Triangle Park, NC 27709. Phone: 919-541-2328; Fax: 919-541-3970. E-mail: Waalkes{at}niehs.nih.gov
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 3 (6)
June 2004
Volume 3, Issue 6
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
Jie Liu, Chengxiu Li, Wei Qu, Elaine Leslie, Challice L. Bonifant, Gregory S. Buzard, Joseph E. Saavedra, Larry K. Keefer and Michael P. Waalkes
Mol Cancer Ther June 1 2004 (3) (6) 709-714;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
Jie Liu, Chengxiu Li, Wei Qu, Elaine Leslie, Challice L. Bonifant, Gregory S. Buzard, Joseph E. Saavedra, Larry K. Keefer and Michael P. Waalkes
Mol Cancer Ther June 1 2004 (3) (6) 709-714;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells
  • Involvement of base excision repair in response to therapy targeted at thymidylate synthase
  • Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement